MedTrace Logo

Curcumin for Pediatric Nonalcoholic Fatty Liver Disease

NCT04109742 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2021-09-27

No results posted yet for this study

Summary

This is a single-center, randomized, double-blinded, placebo-controlled, parallel treatment groups phase 2a study of curcumin for pediatric nonalcoholic fatty liver disease (NAFLD).

Conditions

  • NAFLD - Nonalcoholic Fatty Liver Disease
  • NASH - Nonalcoholic Steatohepatitis

Interventions

DRUG

phosphatidylcholine-curcumin complex supplement

a dietary curcumin supplement given at two different doses

DRUG

Placebo curcumin capsule

matching placebo to active curcumin capsules

Sponsors & Collaborators

Principal Investigators

  • Joel E Lavine, MD, PhD · Columbia University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
8 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-09
Primary Completion
2020-04-22
Completion
2020-04-22
FDA Drug
Yes

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04109742 on ClinicalTrials.gov